ARQTHealthcareMid-Cap
Arcutis Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Arcutis Biotherapeutics, Inc. (ARQT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ARQT insiders buying or selling?
Arcutis Biotherapeutics, Inc. insiders reported 20 open-market buys ($71.6M) and 237 sells ($60.7M) across 257 Form 4 filings — a net buying position of $10.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Aug 28, 2026)
Total Form 4 filings
257
SEC EDGAR
Insider filers
24
Insider buys (20)
$71.6M
Insider sells (237)
$60.7M
Insider sentiment
Net buyingNet insider flow of $10.9M in net buying.
Recent ARQT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Terrie Curran | Director | Sale | 38.2K | $25.03 | $956.1K |
| Aug 24, 2026 | Terrie Curran | Director | Sale | 1.1K | $26.04 | $27.9K |
| Aug 21, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 1.7K | $27.00 | $45.8K |
| Aug 19, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $26.18 | $123.8K |
| Aug 14, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 15.0K | $26.33 | $394.9K |
| Aug 6, 2026 | Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | Sale | 955 | $26.12 | $24.9K |
| Aug 6, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 1.2K | $26.12 | $32.1K |
| Aug 6, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 4.4K | $26.12 | $114.3K |
| Jul 17, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $26.91 | $127.3K |
| Jun 18, 2026 | Sue-Jean Lin | Director | Sale | 4.9K | $24.38 | $120.6K |
| Jun 18, 2026 | Howard G. Welgus | Director | Sale | 4.7K | $24.58 | $116.3K |
| May 13, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 435 | $21.05 | $9.2K |
| May 13, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 222 | $21.05 | $4.7K |
| May 6, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 8.3K | $23.31 | $192.4K |
| May 6, 2026 | Patrick Burnett | Reporting Person's Title: EVP, Chief Medical Officer | Sale | 684 | $23.61 | $16.1K |
| May 6, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 1.3K | $23.61 | $31.7K |
| May 6, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 3.2K | $23.61 | $74.9K |
| May 6, 2026 | Howard G. Welgus | Director | Sale | 7.1K | $22.99 | $164.2K |
| Apr 3, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $23.88 | $238.8K |
| Mar 4, 2026 | Keith R Leonard | Director | Sale | 39.3K | $25.39 | $997.2K |
| Mar 4, 2026 | Howard G. Welgus | Director | Sale | 10.0K | $25.65 | $256.5K |
| Mar 4, 2026 | Larry Todd Edwards | Reporting Person's title: EVP, Chief Commercial Officer | Sale | 3.7K | $25.18 | $92.8K |
| Mar 4, 2026 | Todd Watanabe | Reporting Person's title: President and Chief Executive Officer | Sale | 37.3K | $25.18 | $940.5K |
| Mar 4, 2026 | Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | Sale | 12.1K | $26.03 | $313.9K |
| Mar 4, 2026 | Latha Vairavan | SVP Chief Financial Officer | Sale | 2.9K | $25.18 | $71.8K |
Showing the 25 most recent of 257 Form 4 filings for Arcutis Biotherapeutics, Inc..
Most active ARQT insiders
- Todd Watanabe59 filings
- Howard G. Welgus56 filings
- Patrick Burnett33 filings
- Masaru Matsuda25 filings
- David W Osborne9 filings
Ask anything about ARQT insider activity
Use Trabud's AI agent to query Arcutis Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me ARQT CEO purchases this year" or compare it against any other ticker.
Open the AI agentARQT insider trading FAQ
Are Arcutis Biotherapeutics, Inc. insiders buying or selling?
Across 257 SEC Form 4 filings, Arcutis Biotherapeutics, Inc. (ARQT) insiders reported 20 open-market purchases totaling $71.6M and 237 sales totaling $60.7M. That is a net buying position of $10.9M.
How many insiders trade ARQT stock?
24 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Arcutis Biotherapeutics, Inc.. The most recent filing was accepted on Aug 28, 2026.
Where does Trabud get ARQT insider trading data?
All ARQT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.